Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion

Campochiaro, Peter A.; Heier, Jeffrey S.; Feiner, Leonard; Gray, Sarah; Saroj, Namrata; Rundle, Amy Chen; Murahashi, Wendy Yee; Rubio, Roman G.

doi:10.1016/j.ophtha.2010.02.021

Cited by 797 publications

(779 citation statements)

References 15 publications

Supporting

Mentioning

712

Contrasting

Unclassified

Order By: Relevance

“…Research has demonstrated the benefit of anti-VEGF injections for 'centre-involved' diabetic macular oedema, 9 central retinal vein occlusion, 10 and branch retinal vein occlusion. 11 NICE has recently approved the use of ranibizumab for diabetic macular oedema and retinal vein occlusions, and this will result in even more pressure on the resources of NHS eye units across the UK. NP-delivered anti-VEGF injections is one solution to assist in meeting these extra demands and this method of service delivery has recently been endorsed by the Royal College of Ophthalmologists (Intra-ocular injections by non-medical health care professionals, Royal College of Ophthalmologists statement, 01/05/2013) and the Macular Society.…”

Section: Discussionmentioning

confidence: 99%

A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners

Simcock

Kingett

Mann

et al. 2014

Eye

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners

Simcock

Kingett

Mann

et al. 2014

Eye

View full text Add to dashboard Cite

show abstract

“…32 Following dexamethasone, ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA, USA; Novartis Pharma AG, Basel, Switzerland) intravitreal injection was also approved in the United States for the same indication on the basis of two multicenter, randomized, doublemasked clinical trials (BRAVO and CRUISE). 33,34 In these clinical trials, both dexamethasone and ranibizumab demonstrated clinically and statistically improved vision acuity compared with placebo. In GENEVA, 23 and 18% of patients with BRVO and CRVO, respectively, gained at least three lines (15 letters) of best-corrected visual acuity (BCVA) in the first 3 months after treatment with dexamethasone intravitreal implant, compared with 20 and 12% in the respective sham groups.…”

Section: Risk Of Vascular and Cardiovascular Complications In Rvomentioning

confidence: 99%

“…32 In BRAVO and CRUISE, after 6 months of ranibizumab therapy, between 55 and 61% of patients with BRVO gained at least three lines of BCVA (compared with 28% in the sham group) and about 48% of patients with CRVO gained at least three lines of BCVA (compared with 17% in the sham group). 33,34 Intravitreal triamcinolone acetonide has also been investigated and was shown to be superior to observation in CRVO but failed to demonstrate superiority in efficacy or safety over grid photocoagulation in BRVO in a multicenter phase III SCORE study. 35,36 Although this article was under review, the Royal College of Ophthalmologists' guidelines were updated to recommend consideration of dexamethasone intravitreal implant and ranibizumab for managing macular edema following CRVO and BRVO.…”

Section: Risk Of Vascular and Cardiovascular Complications In Rvomentioning

confidence: 99%

The burden of disease of retinal vein occlusion: review of the literature

Laouri¹,

E²,

Looman³

et al. 2011

Eye

218

154

View full text Add to dashboard Cite

Retinal vein occlusion (RVO) is the second most common cause of vision loss due to retinal vascular disease. A literature review was undertaken to understand the epidemiology, clinical consequence, current practice patterns, and cost of RVO. Pertinent articles were identified by computerized searches of the English language literature in MEDLINE supplemented with electronic and manual searches of society/association proceedings and bibliographies of electronically identified sources. Populationbased studies report a prevalence rate of 0.5-2.0% for branch RVO and 0.1-0.2% for central RVO. The 15-year incidence rate is estimated to be 1.8% for branch RVO and 0.2% for central RVO. Patients with RVO report lower vision-related quality of life than those without ocular disease. Available treatment options are limited. Until recently there was no treatment for central RVO. Laser photocoagulation is only recommended for branch RVO in patients who have not experienced severe vision loss. Emerging evidence on the effectiveness of intravitreal anti-vascular endothelial growth factor therapy and dexamethasone intravitreal implant is promising. Information on the treatment patterns and cost of RVO is extremely limited with one retrospective analysis of secondary insurance payment data identified and limited to the United States population only. A better understanding of the economic and societal impact of RVO will help decision makers evaluate emerging medical interventions for this sight-threatening disease.

show abstract

“…These demographic characteristics are unusual in daily medical practice and could account for differences with other published studies. [7][8][9] Furthermore, the mean age of the patients enrolled (69.3 years; ± 12.2 years) was higher (although not significantly) than those in the Geneva study group (64.7 years; range 33-90 years). 7 Mean BCVA at baseline was poor in our population (20/200 Snellen equivalent; +0.98(0.56) LogMAR; about 35 letters translated into the ETDRS grading scale) compared to 54.3, 51, and 48 letters in the Geneva study group, SCORE study and CRUISE Trial, respectively.…”

Section: Discussionmentioning

confidence: 75%

“…The BRAVO, CRUISE, and GENEVA trials are three studies that have demonstrated the efficacy of anti-VEGF agents and DEX implants, but they cannot serve as comparative studies. 7,8,10 For example, two-thirds of the patients included in the BRAVO and CRUISE (ranibizumab) studies had more recent onset macular edema (short duration ≤ 90 days) than patients in the GENEVA study (only 16% ≤ 90 days). A shorter duration of ME was associated with greater improvements in BCVA after DEX implant.…”

Section: Eyementioning

confidence: 99%

Anatomical and functional recurrence after dexamethasone intravitreal implants: a 6-month prospective study

Fortoul

Denis

Kodjikian

2015

Eye

View full text Add to dashboard Cite

Purpose To evaluate the efficacy, safety, and delay of anatomical and functional recurrence after a first intravitreal injection of dexamethasone implant in eyes with cystoid macular edema (CME) secondary to retinal vein occlusion (RVO). Methods A 6-month prospective, monocentric and noncomparative case-series of 26 eyes of 26 patients. Best-corrected visual acuity (BCVA) and central subfield thickness (CST) were measured at baseline and each visit at 1 week, and months 1, 2, 3, 4, 5, and 6 after a first treatment. Primary efficacy outcome was the proportion of eyes with a minimum three-line improvement from baseline BCVA at each visit and at 6 months. We also defined different patterns of recurrence: qualitative anatomical recurrence, quantitative anatomical recurrence and functional recurrence. A P-value o5% was considered statistically significant. Results Mean population age was 69.3 years (SD = 12.2; range = 42-94 years). Mean ME duration before treatment was~9.2 months (SD = 11.43; range = 0.4-40 months). Eighty eight percent of eyes achieved a three-line improvement from baseline at 2 months (P = 0.02). The mean delay from baseline until qualitative anatomical, functional, or quantitative anatomical recurrence was 4.11 months (±0.86), 4.31 months (±1.33), and 4.40 months (±1.14), respectively. Qualitative anatomical recurrence occurred on average 14.4 days (SD = 42.18) before a minimum of one-line BCVA impairment (functional recurrence). Conclusion Dexamethasone intravitreal treatment seems to be effective for ME after RVO even with long-duration ME or poor visual acuity before treatment. Other longer studies should assess the delay of recurrence after second and further treatments with DEX implants or combined therapies for ME after RVO.

show abstract

Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion

Cited by 797 publications

References 15 publications

A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners

A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners

The burden of disease of retinal vein occlusion: review of the literature

Anatomical and functional recurrence after dexamethasone intravitreal implants: a 6-month prospective study

Contact Info

Product

Resources

About